JPRN-UMIN000003128
Completed
未知
Supplemental treatment of rheumatoid arthritis with natural milk antibodies against enteromicrobes and their toxins - Supplemental treatment of rheumatoid arthritis with natural milk antibodies
Asama Chemical Co. Ltd.,0 sites40 target enrollmentFebruary 15, 2010
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Asama Chemical Co. Ltd.,
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with milk allergy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Research into lower dosing of tofacitinib (Xeljanz®) when used in combination with cobicistat (Tybost®), a drug that reduces drug breakdowRheumatoid Arthritis, Psoriatic ArthritisNL-OMON26019Radboudumc30
Active, not recruiting
Phase 1
REDO study: Research into the effects of lower doses rituximab in patients with rheumatoid arthritisEUCTR2016-002908-15-NLSint Maartenskliniek140
Completed
Not Applicable
BIOmarker-driven DEcision Study with Adalimumab (BIODESA)ISRCTN61158084niversity Hospital Regensburg (Universitätsklinikum Regensburg) (Germany)60
Recruiting
Phase 1
Exploratory study for the treatment of rheumatoid arthritis by eliminating dampnessRheumatoid ArthritisITMCTR2000003354Guangdong Provincial Hospital of Chinese Medicine
Completed
Phase 4
RhEumatoid arthritis REtreatment with ultra-low dose Rituximab: Disease Outcome after Dose Optimizatiochronic inflammation of the jointsRheumatoid arthritis1000381610023213NL-OMON47117Sint Maartenskliniek140